Description: Simcere Pharmaceutical Group Limited engages in the research, development, manufacture, and sale of pharmaceutical products for distributors and pharmacy chains and other pharmaceutical manufacturers in China. The company focusses on various therapeutic areas, including oncology, central nervous system, autoimmune, anti-infection, cardiovascular, and others. Its principal products include Sanbexin, an edaravone and dexborneol concentrated solution for injection; Endostar, a recombinant human endostatin injection; ENWEIDA, an envafolimab injection; COSELA, a trilaciclib hydrochloride for injection; Iremod, an iguratimod tablet; and XIANNUOXIN, a simnotrelvir tablets/ritonavir tablets. The company also offers promotion services for pharmaceutical products. It has a strategic regional licensing partnership with Vivoryon Therapeutics N.V. to develop and commercialize SIM0801 and other drugs in the Greater China region. In addition, the company engages in the manufacture of pharmaceutical ingredients; and property management business. Simcere Pharmaceutical Group Limited was founded in 1995 and is headquartered in Nanjing, China.
Home Page: www.simcere.com
No. 699-18, Xuanwu Road
Nanjing,
210042
China
Phone:
86 25 8556 6666
Officers
| Name | Title |
|---|---|
| Mr. Jinsheng Ren | Co-Founder, Chairman & CEO |
| Mr. Yushan Wan | CFO, Joint Company Secretary & Executive Director |
| Mr. Renhong Tang Ph.D. | Executive Director |
| Ms. Xi Wang | VP & Executive Director |
| Mr. Gaobo Zhou | Chief Investment Officer |
| Mr. Quanfu Feng | Vice President of Marketing |
| Dr. Tamas Oravecz Ph.D. | Senior VP & Chief Scientific Officer of Simcere Zaiming |
| Dr. Aik Han Goh | Senior VP & Chief Medical Officer |
| Mr. Wang John | Senior Vice President |
| Dr. Yongyu Wang | Senior VP & Chief Medical Officer of Simcere Zaiming |
Exchange: PINK
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 17.305 |
| Price-to-Book MRQ: | 1.7832 |
| Price-to-Sales TTM: | 0.2793 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 6412 |